Thomas WG - Search Results

1

Cardiovascular role of urotensin II: effect of chronic infusion in the rat.

Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD, Krum H. Kompa AR, et al. Among authors: thomas wg. Peptides. 2004 Oct;25(10):1783-8. doi: 10.1016/j.peptides.2004.03.029. Peptides. 2004. PMID: 15476946 Review.

2

Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.

Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Tzanidis A, et al. Among authors: thomas wg. Circ Res. 2003 Aug 8;93(3):246-53. doi: 10.1161/01.RES.0000084382.64418.BC. Epub 2003 Jul 3. Circ Res. 2003. PMID: 12842917

3

Urotensin II: the old kid in town.

Onan D, Hannan RD, Thomas WG. Onan D, et al. Among authors: thomas wg. Trends Endocrinol Metab. 2004 May-Jun;15(4):175-82. doi: 10.1016/j.tem.2004.03.007. Trends Endocrinol Metab. 2004. PMID: 15109617 Review.

4

p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.

See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H. See F, et al. J Am Coll Cardiol. 2004 Oct 19;44(8):1679-89. doi: 10.1016/j.jacc.2004.07.038. J Am Coll Cardiol. 2004. PMID: 15489104 Free article.

5

Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases.

Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Onan D, et al. Among authors: thomas wg. Mol Endocrinol. 2004 Sep;18(9):2344-54. doi: 10.1210/me.2003-0309. Epub 2004 Jun 17. Mol Endocrinol. 2004. PMID: 15205471

6

Tackling the EGFR in pathological tissue remodelling.

Chan HW, Smith NJ, Hannan RD, Thomas WG. Chan HW, et al. Among authors: thomas wg. Pulm Pharmacol Ther. 2006;19(1):74-8. doi: 10.1016/j.pupt.2005.04.005. Epub 2005 Jun 24. Pulm Pharmacol Ther. 2006. PMID: 15979363 Review.

7

Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches.

George AJ, Hannan RD, Thomas WG. George AJ, et al. Among authors: thomas wg. FEBS J. 2013 Nov;280(21):5258-68. doi: 10.1111/febs.12509. Epub 2013 Sep 23. FEBS J. 2013. PMID: 23992425 Free article. Review.

8

Effect of dominant-negative epidermal growth factor receptors on cardiomyocyte hypertrophy.

Chan HW, Jenkins A, Pipolo L, Hannan RD, Thomas WG, Smith NJ. Chan HW, et al. Among authors: thomas wg. J Recept Signal Transduct Res. 2006;26(5-6):659-77. doi: 10.1080/10799890600923187. J Recept Signal Transduct Res. 2006. PMID: 17118804

9

The renin-angiotensin system and cancer: old dog, new tricks.

George AJ, Thomas WG, Hannan RD. George AJ, et al. Among authors: thomas wg. Nat Rev Cancer. 2010 Nov;10(11):745-59. doi: 10.1038/nrc2945. Epub 2010 Oct 22. Nat Rev Cancer. 2010. PMID: 20966920 Review.

10

Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor.

Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Thomas WG, et al. Circ Res. 2002 Feb 8;90(2):135-42. doi: 10.1161/hh0202.104109. Circ Res. 2002. PMID: 11834705

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

173 results

Search Page

Filters